logo
Plus   Neg
Share
Email

PSEG Announces Infrastructure Investment Program - Quick Facts

PSEG (PEG) outlined a plan to invest $14 billion to $17 billion over the next five years which will help New Jersey become a clean energy leader. The company's infrastructure program, an expansion of previously disclosed plans to invest $11.5 billion to $13.2 billion over the five-year period ending in 2022, includes a proposal for a significant increase in the utility's investments in energy efficiency, as well as the first major investment in electric vehicle infrastructure. The program, if approved, provides an opportunity for annual growth of 8 percent to 10 percent in PSE&G's rate base.

PSEG estimates that the energy efficiency program will generate approximately 5,000 sustainable direct and indirect jobs over the six-year life of the program, reduce CO2 emissions by 24 million tons and reduce energy use by 40 million MWh of electricity and 675 million therms of natural gas.

PSEG further announced that PSEG Power, the company's merchant generation and power marketing business, will continue to transition to a more efficient, productive and clean power generation fleet.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Shares of Volkswagen Group were gaining around 3 percent in German trading after the automotive giant Thursday reported market recovery in the third quarter with improved deliveries in the month of September. For the first nine months of fiscal 2020, the company, meanwhile reported sharply lower earnings with weak revenues and sales volume. Comcast Corp. on Thursday reported a 37 percent decline in profit for the third quarter from last year, hurt primarily by revenue decline at NBCUniversal. Both adjusted earnings per share and quarterly revenues topped analysts' expectations. The company also declared a quarterly dividend. In the pre-market trade, CMCSA is trading at $42.83, up $0.85 or 2.02 percent. Regeneron announced positive results from its late stage COVID-19 outpatient trial, indicating that its antibody cocktail therapy significantly reduced virus levels and need for further medical attention. The trial results showed that investigational antibody cocktail, REGN-COV2, met the primary and key secondary endpoints.
Follow RTT